Inhibrx, Inc.

Inhibrx Biosciences, Inc.

Rajay A Pandit

Brendan P Eckelman

John C Timmer

Quinn L Deveraux

Amir S Razai

Abrahim Hussain

Lucas Rascon

Mike Kaplan

Angelica N Sanabria

Kyle S Jones

Bryan Becklund

Chelsie Macedo

Katelyn M Willis

Florian Sulzmaier

Michael D Kaplan

Chelsie Hata

Sydney A Barnes

Margaret E Haerr

Provided herein are binding polypeptides that specifically bind DLL3. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific contracts and chimeric antigen receptors, that bind DLL3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided DLL3 binding polypeptides for treating diseases and conditions, such as cancer.

DLL3 single domain antibodies and therapeutic compositions thereof

Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.

PD-1 single domain antibodies and therapeutic compositions thereof

This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.

Multivalent and multispecific OX40-binding fusion proteins

The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.

Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same

This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.

Multivalent and multispecific 41BB-binding proteins

PDL1-binding proteins

Multivalent and multispecific 41BB-binding fusion proteins

Growing community of inventors

La Jolla, CA, United States of America

Rajay A Pandit